

Curdin Conrad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3615364/publications.pdf>

Version: 2024-02-01

80
papers

7,917
citations

109321
35
h-index

66911
78
g-index

86
all docs

86
docs citations

86
times ranked

10091
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNAâ€“Peptide Complexes in Systemic Lupus Erythematosus. <i>Science Translational Medicine</i> , 2011, 3, 73ra19.	12.4	1,080
2	Plasmacytoid predendritic cells initiate psoriasis through interferon- γ production. <i>Journal of Experimental Medicine</i> , 2005, 202, 135-143.	8.5	999
3	Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor- γ . <i>Journal of Experimental Medicine</i> , 2004, 199, 731-736.	8.5	463
4	The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. <i>Nature Communications</i> , 2014, 5, 5621.	12.8	427
5	Psoriasis Triggered by Toll-like Receptor 7 Agonist Imiquimod in the Presence of Dermal Plasmacytoid Dendritic Cell Precursors. <i>Archives of Dermatology</i> , 2004, 140, 1490-5.	1.4	364
6	Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. <i>Nature Medicine</i> , 2005, 11, 138-145.	30.7	356
7	Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. <i>Journal of Experimental Medicine</i> , 2010, 207, 2921-2930.	8.5	292
8	The cGASâ€“STING pathway drives type I IFN immunopathology in COVID-19. <i>Nature</i> , 2022, 603, 145-151.	27.8	272
9	Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells. <i>Cancer Research</i> , 2012, 72, 5240-5249.	0.9	267
10	α 1 β 1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. <i>Nature Medicine</i> , 2007, 13, 836-842.	30.7	241
11	Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis. <i>Journal of Immunology</i> , 2010, 185, 5688-5691.	0.8	207
12	TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. <i>Nature Communications</i> , 2018, 9, 25.	12.8	194
13	Dendritic-cell-based therapeutic vaccination against cancer. <i>Current Opinion in Immunology</i> , 2005, 17, 163-169.	5.5	182
14	TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. <i>Nature Immunology</i> , 2015, 16, 970-979.	14.5	182
15	Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1143-1153.	6.3	173
16	Psoriasis: from Pathogenesis to Targeted Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 102-113.	6.5	151
17	Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to selfâ€“DNA. <i>European Journal of Immunology</i> , 2015, 45, 203-213.	2.9	129
18	The pathogenic role of tissue-resident immune cells in psoriasis. <i>Trends in Immunology</i> , 2007, 28, 51-57.	6.8	128

#	ARTICLE	IF	CITATIONS
19	Targeting CD8+ T cells prevents psoriasis development. Journal of Allergy and Clinical Immunology, 2016, 138, 274-276.e6.	2.9	125
20	Interleukin 23â€‘Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. JAMA Dermatology, 2017, 153, 304.	4.1	111
21	Diversification of human plasmacytoid predendritic cells in response to a single stimulus. Nature Immunology, 2018, 19, 63-75.	14.5	106
22	Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Frontiers in Immunology, 2018, 9, 2746.	4.8	96
23	Interplay between keratinocytes and immune cellsâ€‘Recent insights into psoriasis pathogenesis. International Journal of Biochemistry and Cell Biology, 2009, 41, 963-968.	2.8	92
24	The commensal skin microbiota triggers type I IFNâ€‘dependent innate repair responses in injured skin. Nature Immunology, 2020, 21, 1034-1045.	14.5	90
25	Human â€‘T _H 9â€‘cells are a subpopulation of PPAR-Î³ ⁺ T _H 2 cells. Science Immunology, 2019, 4, .	11.9	75
26	Drug Survival of IL-12/23, IL-17 and IL-23 InhibitorsÂ‘for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. American Journal of Clinical Dermatology, 2021, 22, 567-579.	6.7	65
27	Plasmacytoid dendritic cells in the skin: To sense or not to sense nucleic acids. Seminars in Immunology, 2009, 21, 101-109.	5.6	56
28	PASS Syndrome: An IL-1-Driven Autoinflammatory Disease. Dermatology, 2016, 232, 254-258.	2.1	51
29	The IL-12 Family Member p40 Chain as a Master Switch and Novel Therapeutic Target in Psoriasis. Journal of Investigative Dermatology, 2004, 123, xiv-xv.	0.7	49
30	Pyoderma gangrenosum. JDDG - Journal of the German Society of Dermatology, 2005, 3, 334-342.	0.8	49
31	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. Cell Reports, 2018, 25, 3564-3572.e4.	6.4	49
32	Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis.. British Journal of Dermatology, 2005, 152, 1211-1218.	1.5	46
33	IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. Journal of Investigative Dermatology, 2019, 139, 1732-1742.e17.	0.7	42
34	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood Advances, 2019, 3, 3674-3687.	5.2	40
35	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology, 2016, 232, 385-406.	2.1	39
36	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. Journal of the American Academy of Dermatology, 2019, 81, 273-275.	1.2	39

#	ARTICLE	IF	CITATIONS
37	Melanoma and innate immunity – Active inflammation or just erroneous attraction?. Seminars in Cancer Biology, 2009, 19, 84-91.	9.6	35
38	Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. Dermatology, 2016, 232, 640-647.	2.1	32
39	The biological basis of disease recurrence in psoriasis: a historical perspective and current models. British Journal of Dermatology, 2022, 186, 773-781.	1.5	32
40	Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatology and Therapy, 2020, 10, 663-670.	3.0	28
41	Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature. International Journal of Molecular Sciences, 2020, 21, 5102.	4.1	26
42	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 123-134.	2.4	25
43	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Journal of Dermatological Treatment, 2020, 31, 476-483.	2.2	23
44	Biomarkers of disease progression in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 481-493.	1.5	22
45	Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study*. British Journal of Dermatology, 2021, 185, 1160-1168.	1.5	21
46	Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. Journal of Dermatological Treatment, 2022, 33, 1652-1660.	2.2	20
47	Trauma as Triggering Factor for Development of Melanocytic Nevi. Dermatology, 2010, 220, 291-296.	2.1	18
48	Type I IFNs at the Interface between Cutaneous Immunity and Epidermal Remodeling. Journal of Investigative Dermatology, 2012, 132, 1759-1762.	0.7	18
49	Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. Dermatology, 2016, 232, 655-663.	2.1	18
50	Animal models of psoriasis and psoriatic arthritis: An update. Current Rheumatology Reports, 2006, 8, 342-347.	4.7	17
51	Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment. OncoImmunology, 2013, 2, e23887.	4.6	17
52	Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology, 2021, 237, 166-178.	2.1	17
53	Mechanisms of psoriasis. Drug Discovery Today Disease Mechanisms, 2004, 1, 315-319.	0.8	16
54	Current State and Perspectives of Dendritic Cell Vaccination in Cancer Immunotherapy. Skin Pharmacology and Physiology, 2006, 19, 124-131.	2.5	16

#	ARTICLE	IF	CITATIONS
55	Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021—a two-round Delphi survey among international experts. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1467-1476.	2.4	14
56	Biomarkers of systemic treatment response in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 494-506.	1.5	14
57	The Dermatologists' Role in Managing Psoriatic Arthritis: Results of a Swiss Delphi Exercise Intended to Improve Collaboration with Rheumatologists. Dermatology, 2015, 230, 75-81.	2.1	13
58	Efficacy and safety of <sc>TNF</sc> blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2330-2338.	2.4	13
59	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	4.1	12
60	Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2021, 22, 1650.	4.1	11
61	Dendritic cell-based cancer therapy. Current Opinion in Molecular Therapeutics, 2003, 5, 405-12.	2.8	11
62	Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1578-1583.	2.4	11
63	Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 403-412.	2.4	10
64	Anti-TNF Therapy in the Treatment of Psoriasis in a Patient with Acute-on-Chronic Pancreatitis. Dermatology, 2013, 227, 193-196.	2.1	9
65	New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis. Antibodies, 2021, 10, 12.	2.5	8
66	Xenotransplantation Model of Psoriasis. Methods in Molecular Biology, 2017, 1559, 83-90.	0.9	7
67	Baricitinib-induced paradoxical psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e391-e393.	2.4	6
68	Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. Dermatology and Therapy, 2022, 12, 81-95.	3.0	6
69	Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the <sc>SERENA</sc> study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1796-1804.	2.4	6
70	Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. Psoriasis: Targets and Therapy, 2013, , 1.	2.2	5
71	Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab. British Journal of Dermatology, 2021, 185, 865-867.	1.5	5
72	Interleukin-17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses. Clinical and Experimental Dermatology, 2022, 47, 675-683.	1.3	5

#	ARTICLE	IF	CITATIONS
73	Papillon-Deleuvre syndrome treated by acitretin: case report and cytokine profile. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	4
74	Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis. Dermatology and Therapy, 2022, 12, 233-241.	3.0	4
75	Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab. Journal of the American Academy of Dermatology, 2020, 83, 261-263.	1.2	3
76	TYK-ing all the boxes in psoriasis. Journal of Allergy and Clinical Immunology, 2022, 149, 1936-1939.	2.9	3
77	Purpura of the Face and Neck: An Atypical Clinical Presentation Revealing a Hepatosplenic T Cell Lymphoma. Case Reports in Dermatology, 2014, 6, 37-42.	0.8	2
78	Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2313-2318.	2.4	2
79	Psoriasis, Cutaneous Lupus Erythematosus and Immunobiology of the Skin. , 2016, , 192-203.		0
80	Infections Associated with Immunobiologics. , 2017, , 796-804.e2.		0